Current Month 2010
Article Features
  Breast Cancer Metastasis Increases After Progestin Hormone Therapies
Breast Cancer Staging Should Include Breast MRI
Breast MRI Could Reduce Local Breast Cancer Recurrence Rates
Broccoli Component Limits Breast Cancer Stem Cells
Estrogen Receptor Status of HER2+ Breast Cancer Correlates with Response to Anti-HER Therapies
Genetic Polarity in Breast Tumor Growth
Indeterminate Breast Lesions Found in High-Risk Patients Should Be Evaluated Aggressively to Exclude Malignancy
Key Mechanism Identified in Breast Cancer
Researchers Discover New Way to “Rescue” Treatment Sensitivity of Breast Cancer Cells
Researchers Link Ovarian Hormone to Altering of Breast Stem Cells
Screening Mammograms in Younger Women Have Low Accuracy and Detect Few Cancers
Simple Gene Test Identifies Clinically Important Subtypes of Breast Cancer
Slight Changes in Two Key Genes Appear to Launch Breast Cancer Development
Study Evaluates Importance of Timeliness of Care in Breast Cancer Diagnosis and Treatment
Study Raises New Concerns About Radiation and Breast Cancer
Survival in Metastatic Breast Cancer Directly Linked to Circulating Tumor Cells
Survival in Metastatic Breast Cancer Directly Linked to Circulating Tumor Cells
Whole Body MRI is Highly Accurate in the Early Detection of Breast Cancer Metastases


Study Identifies One of the Mechanisms Behind Breast Cancer Metastasis

Several years ago, scientists at Beth Israel Deaconess Medical Center (BIDMC) and other laboratories made a paradoxical discovery regarding the Akt molecular pathway, a popular target for cancer drug therapies. They discovered that while one Akt protein – Akt1 – was actively preventing cancer cells from spreading, another closely related family member – Akt2 – was actually promoting breast cancer cell migration. And, indeed, subsequent studies in mouse models of breast cancer revealed that blocking the Akt pathway resulted in enhanced metastasis to the lungs.

This left scientists and clinicians faced with a troubling situation: Would the drugs actively being developed to inhibit Akt activity and halt breast cancer survival mechanisms be simultaneously enhancing cancer cells' abilities to metastasize to other organs?

Now, BIDMC scientists Alex Toker, PhD, and Rebecca Chin, PhD, have identified the first direct Akt1 target, a protein called palladin, providing an explanation for how Akt1 can function as a suppressor of breast cancer invasion and metastasis. This new finding, reported in the journal Molecular Cell, reveals another key piece of information as scientists continue their development of targeted cancer therapies, and underscores the importance of dissecting the precise mechanisms by which tumor cells invade and metastasize to distant organs.

Read More of the Main Article

 
Visit the Ezine


Visit the BreastCenter

Visit the Quality Corner
Avon Breast Cancer Crusade - AVON the company for women

  This website is supported in part by an unrestricted educational grant provided by Avon